Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 2
2010 3
2011 1
2016 1
2017 3
2018 3
2019 3
2020 5
2021 7
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystrøm CM, Torp R, Mielnik P, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: goll gl. JAMA. 2021 May 4;325(17):1744-1754. doi: 10.1001/jama.2021.4172. JAMA. 2021. PMID: 33944876 Free PMC article. Clinical Trial.
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia.
Holm S, Kared H, Michelsen AE, Kong XY, Dahl TB, Schultz NH, Nyman TA, Fladeby C, Seljeflot I, Ueland T, Stensland M, Mjaaland S, Goll GL, Nissen-Meyer LS, Aukrust P, Skagen K, Gregersen I, Skjelland M, Holme PA, Munthe LA, Halvorsen B. Holm S, et al. Among authors: goll gl. Eur Heart J. 2021 Oct 14;42(39):4064-4072. doi: 10.1093/eurheartj/ehab506. Eur Heart J. 2021. PMID: 34405870 Free PMC article.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: goll gl. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Clinical Trial.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Among authors: goll gl. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK. Goll GL, et al. J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12. J Intern Med. 2019. PMID: 30762274 Free PMC article. Clinical Trial.
[Biosimilar drugs – just as good, and much cheaper].
Goll GL. Goll GL. Tidsskr Nor Laegeforen. 2019 Mar 19;139(6). doi: 10.4045/tidsskr.19.0051. Print 2019 Mar 26. Tidsskr Nor Laegeforen. 2019. PMID: 30917643 Free article. Norwegian. No abstract available.
31 results